NS-2359: Difference between revisions

{{drugbox | verifiedrevid = 408722899

|

| image = NStwothreefivenine.png

| CAS_number =

| ATC_suffix =

| C = 15 | H = 19 | Cl = 2 | N = 1 | O = 1

| molecular_weight = 300.223 g/mol

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| pregnancy_category =

| legal_status =

| routes_of_administration =

'''NS-2359''' ('''GSK-372,475''') is a [[serotonin-norepinephrine-dopamine reuptake inhibitor]]. It was under [[drug development|development]] by [[GlaxoSmithKline]] (GSK) as an [[antidepressant]],<ref name="urlNeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression">{{cite web | url = https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=313018&messageId=372903 | title = NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression | format = | work = | accessdate = }}</ref> but was discontinued in 2009 when [[phase II]] [[clinical trial]]s turned up disappointing results and did not support further effort by the company.<ref name="urlNeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression"/> NS-2359 was also in clinical trials for the [[therapy|treatment]] of [[attention-deficit hyperactivity disorder|ADHD]],<ref>{{Cite pmid|18554401}}</ref> phase II having been completed in 2007.<ref>http://clinicaltrials.gov/ct2/show/NCT00467428</ref> A trial exploring the effect of NS-2359 on [[cocaine]]-experienced individuals is currently ongoing.<ref>http://clinicaltrials.gov/ct2/show/NCT00032916</ref>

{{Antidepressants}}

{{Antihyperkinetics}}

{{Adrenergics}}

{{Dopaminergics}}

{{Serotonergics}}

[[Category:Serotonin-norepinephrine-dopamine reuptake inhibitors]]

[[Category:Organochlorides]]